#ASH25 | @RabiHannaMD of @ClevelandClinic shares updated results from the RUBY trial, which is investigating reni-cel, an investigational gene-edited autologous hematopoietic stem cell therapy, in patients with severe #SickleCellDisease: 🎥 ➡️

It was great to catch up with Hans Lee (@SarahCannonDocs) at #ASH25, to hear his highlights in #MultipleMyeloma! 🎥 👉 https://t.co/lLqu3qBEKy Dr Lee mentions several key trials presented (MAJESTEC-3, IFM2021-01, & IMMUNOPLANT) and notes the emerging theme of earlier

Want to hear about the potential factors influencing the lack of survival benefit observed in the Phase III VERONA trial of venetoclax plus azacitidine in newly diagnosed HR-MDS?🤔 Then don't miss our interview with Jacqueline Garcia of @DanaFarber from #ASH25: 🎥

At #ASH25, @pongasg of @SylvesterCancer shared insight into the ongoing Phase II TaZa CLL study investigating tafasitamab and zanubrutinib in newly diagnosed patients with CLL. Click here to watch the interview: 👉 https://t.co/jQYqMgbTai 👈 #CLLsm #Leusm #Leukemia #CTSM

Thank you to @Mohty_EBMT for stopping by at #ASH25 last week to share insight into the key advances & developments in GvHD management presented at the meeting!🩸 Watch the interview by clicking here: 👉 https://t.co/5I09oO3nr5 👈 #BMTsm #AMLsm #MDSsm #Myelofibrosis #HemOnc

#ASH25 Highlights | David Sallman of @MoffittNews discusses the efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed AML.🩸 Watch now: 👉 https://t.co/eF6jmKjl6a 👈 #AMLsm #Leusm #HemOnc #CTSM

Watch our interview with @bose_prithviraj (@MDAndersonNews) from #ASH25 to learn about the rationale for combining momelotinib & luspatercept in transfusion-dependent #myelofibrosis and to hear about the early analysis of the ODYSSEY trial combining these two agents: 👉

At #ASH25, @HangQuach1 of @UniMelb presented the updated safety & efficacy results from the MonumenTAL-2 study, which explores the combination of talquetamab + pomalidomide in patients with R/R #MultipleMyeloma. Watch here: 👉 https://t.co/kMCxI663rx #CTSM #MMSM #TrialUpdate

We're thrilled that #ASH25 was a great success!🩸🌎 Thank you to @ASH_hematology for having us on-site for another year. 😁 We had so many insightful conversations with leading experts, which we are sharing here: 👉 https://t.co/wWOE5eT3rK 👈 Make sure to keep an eye out for

It was a pleasure to catch up with Paolo Strati of @MDAndersonNews at #ASH25 to hear about a Phase II trial of evorpacept, lenalidomide & rituximab for high-tumor-burden indolent B-NHL. Check out the interview here: 🎥 https://t.co/3CNgNSoocE #CTSM #TrialUpdate #LYMsm

🚨Hear results from the PARADIGM trial comparing aza-ven to conventional induction chemo in newly diagnosed fit adults with AML! Watch our interview with Amir Fathi (@MassGenBrigham) from #ASH25: 👉 https://t.co/YwkttoFqxE 👈 #AMLsm #leusm #TrialUpdate #CTSM #Leukemia

Explore our Top 5 updates from #ASH25 🇺🇸🩸🔬👇 📌 Updated results from KOMET-007: ziftomenib plus aza-ven in R/R NPM1-m or KMT2A-r AML - Amir T. Fathi, MD, MPH👉 https://t.co/sfAdkHMoyx 📌 Mosunetuzumab + zanubrutinib for newly diagnosed high-burden FL: first results of

#ASH25 Highlights | Constantine Tam (@AlfredHealth, @MonashUni) shares long-term follow-up data from the SEQUOIA study investigating zanubrutinib versus bendamustine and rituximab in treatment-naive CLL. Watch here: 🎥 https://t.co/TRRzPxcgVy #CLLsm #Leusm #TrialUpdate

Lovely to kick off our final day at #ASH25 speaking with @FrancescoMaura4! We heard about all things genomics, novel sequencing panels, and exciting updates on the use of ctDNA in myeloma. Check out our ASH content now: https://t.co/WmMZj7H6mV #MMsm #HemOnc #ImmunoOnc

These cozy knitted stockings are perfect for keeping your feet warm on chilly winter nights. Whether you’re lounging around the house, watching TV, or wearing slippers or shoes, they add comfort and style to your everyday moments.

#ASH25 IV iron in hospitalized patients with iron-deficiency anemia and active infection seems to be safe and doesn’t worsen survival.

Cell therapy legend Prof. Rainer Storb, recipient of the Wallace H. Coulter Award, prefacing the #ASH25 Plenary Session in front of a packed room. 🙌 @fredhutch #fanboy

🚨 #AML breakthroughs from #ASH25, chaired by @Daver_Leukemia 🔬 Join Dr Naval Daver (Chair) with Dr Courtney DiNardo and Prof. @charliecraddock (Moderators) for an expert-led discussion on the most significant AML data and abstracts from the 67th ASH Annual Meeting and

#ASH25 👉👉👉A most brilliant time spending a few quality moments with Professor @charliecraddock at @ASH_hematology discussing the importance of clinical trial networks across the world for rare blood cancers! #leusm #MPNSM #BPDCN | @Daver_Leukemia @VJHemOnc @sanamloghavi

Kudos to @Othman_Al_Sawaf for his outstanding presentation at the #ASH25 Plenary Session presenting the CLL17 trial: FDT (VO, VI) showed non-inferiority PFS compared with continuous BTKi ibrutinib #hematology #CLL #lymsm

Wow this is beautiful work @KellyLBolton looking at CDK4/6 inhibitors as CHIP-protection in solid tumor pts getting chemo! #ASH25